Header Logo

Connection

SALIM VIRANI to Dyslipidemias

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Dyslipidemias.
SALIM VIRANI
Connection Strength
9.921
Dyslipidemias
  1. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:2-6.
    View in: PubMed
    Score: 0.614
  2. Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? Eur Heart J. 2020 10 21; 41(40):3910-3912.
    View in: PubMed
    Score: 0.581
  3. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.575
  4. Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia. Circulation. 2020 04 07; 141(14):1121-1123.
    View in: PubMed
    Score: 0.560
  5. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. J Am Heart Assoc. 2020 02 04; 9(3):e013600.
    View in: PubMed
    Score: 0.553
  6. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
    View in: PubMed
    Score: 0.543
  7. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.526
  8. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.519
  9. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.514
  10. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.489
  11. Cholesterol Guidelines: More Similar Than Different. Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):190-199.
    View in: PubMed
    Score: 0.434
  12. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components. Tex Heart Inst J. 2016 Aug; 43(4):313-4.
    View in: PubMed
    Score: 0.434
  13. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.424
  14. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Tex Heart Inst J. 2013; 40(3):288-9.
    View in: PubMed
    Score: 0.338
  15. Implementation strategies to improve non-HDL-cholesterol goal attainment: current evidence and a conceptual framework for future directions. Tex Heart Inst J. 2012; 39(2):228-30.
    View in: PubMed
    Score: 0.316
  16. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011; 38(2):160-2.
    View in: PubMed
    Score: 0.294
  17. A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
    View in: PubMed
    Score: 0.167
  18. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17(1):75.
    View in: PubMed
    Score: 0.167
  19. Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):114-121.
    View in: PubMed
    Score: 0.150
  20. Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies. Curr Diabetes Rev. 2021; 17(9):e011221190238.
    View in: PubMed
    Score: 0.147
  21. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. J Am Heart Assoc. 2019 10; 8(19):e013229.
    View in: PubMed
    Score: 0.135
  22. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005562.
    View in: PubMed
    Score: 0.134
  23. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019 04 01; 40(2):537-557.
    View in: PubMed
    Score: 0.130
  24. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018 06 13; 7(12).
    View in: PubMed
    Score: 0.123
  25. Statin Use and Adverse Effects Among Adults >75?Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018 05 08; 7(10).
    View in: PubMed
    Score: 0.123
  26. Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. Circ Cardiovasc Qual Outcomes. 2018 03; 11(3):e004249.
    View in: PubMed
    Score: 0.121
  27. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel?Survey. J Am Heart Assoc. 2018 01 22; 7(2).
    View in: PubMed
    Score: 0.120
  28. Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A?Critique. Am J Med. 2016 09; 129(9):906-12.
    View in: PubMed
    Score: 0.107
  29. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). Am J Cardiol. 2015 Aug 15; 116(4):547-53.
    View in: PubMed
    Score: 0.100
  30. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.092
  31. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014 Jan 07; 129(1):77-86.
    View in: PubMed
    Score: 0.089
  32. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.
    View in: PubMed
    Score: 0.087
  33. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
    View in: PubMed
    Score: 0.079
  34. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.077
  35. Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
    View in: PubMed
    Score: 0.062
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.